EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia A

Christina Hart, Robert Klamroth, Ulrich J Sachs, Richard Greil, Paul Knoebl, Johannes Oldenburg, Wolfgang Miesbach, Christian Pfrepper, Karolin Trautmann-Grill, Isabell Pekrul, Katharina Holstein, Hermann Eichler und 4 weitere

Journal of Thrombosis and Haemostasis · 2024

DOI: 10.1016/j.jtha.2024.06.010 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024. Verfasst von Christina Hart und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany. Hauptthemen laut MEDLINE: Hemophilia A, Antibodies, Monoclonal, Humanized, Antibodies, Bispecific, Immunosuppressive Agents. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Acquired hemophilia A (AHA) is an autoimmune bleeding disorder caused by neutralizing antibodies against coagulation factor VIII. Immunosuppressive therapy (IST) is standard of care to eradicate autoantibody production and protect from further bleeding but carries a risk of severe infection and mortality in frail patients with AHA. Recently, emicizumab has been studied for its potential to reduce the need for early and aggressive IST. OBJECTIVES: To compare outcomes of 2 studies that used either IST (GTH-AH 01/2010; N = 101) or prophylaxis with emicizumab (GTH-AHA-EMI; N = 47) early after diagnosis of AHA. METHODS: Baseline characteristics were balanced by propensity score matching. Primary endpoint was the rate of clinically relevant new bleeds during the first 12 weeks; secondary endpoints were adverse events and overall survival. RESULTS: The negative binominal model-based bleeding rate was 68% lower with emicizumab as compared with IST (incident rate ratio, 0.325; 95% CI, 0.182-0.581). No difference was apparent in the overall frequency of infections (emicizumab 21%, IST 29%) during the first 12 weeks, but infections were less often fatal in emicizumab-treated patients (0%) compared with IST-treated patients (11%). Thromboembolic events occurred less often with emicizumab (2%) than with IST (7%). Overall survival after 24 weeks was better with emicizumab (90% vs 76%; hazard ratio, 0.44; 95%, CI, 0.24-0.81). CONCLUSION: Using emicizumab instead of IST in the early phase after initial diagnosis of AHA reduced bleeding and fatal infections and improved overall survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AAntibodies, Monoclonal, HumanizedAntibodies, BispecificImmunosuppressive AgentsHemorrhageFactor VIIIHumansAgedMaleFemaleTreatment OutcomeAged, 80 and overMiddle AgedTime FactorsPropensity Score

Stichwörter der Autor:innen

autoimmune hemophiliabispecific antibodybleedingimmunosuppressioninhibitor

Substanzen

emicizumabAntibodies, Monoclonal, HumanizedAntibodies, BispecificImmunosuppressive AgentsFactor VIIIF8 protein, human

Autor:innen und Institutionen

  • Department of Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany.
  • Internal Medicine, Vivantes Clinic Friedrichshain, Berlin, Germany.
  • Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, Germany.
  • Medical Department III, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Salzburg, Austria.
  • Hematology and Hemostasis, Vienna Medical University, Vienna, Austria.
  • Institute of Experimental Hematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany.

Zitieren

APA

Hart, C., Klamroth, R., Sachs, U. J., Greil, R., Knoebl, P., Oldenburg, J., Miesbach, W., Pfrepper, C., Trautmann-Grill, K., Pekrul, I., Holstein, K., Eichler, H., Weigt, C., Schipp, D., Werwitzke, S., & Tiede, A. (2024). Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia A. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.06.010

Vancouver

Hart C, Klamroth R, Sachs UJ, Greil R, Knoebl P, Oldenburg J, et al. Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia A. Journal of Thrombosis and Haemostasis. 2024. doi:10.1016/j.jtha.2024.06.010

BibTeX
@article{Hart2024,
  author = {Hart, Christina and Klamroth, Robert and Sachs, Ulrich J and Greil, Richard and Knoebl, Paul and Oldenburg, Johannes and Miesbach, Wolfgang and Pfrepper, Christian and Trautmann-Grill, Karolin and Pekrul, Isabell and Holstein, Katharina and Eichler, Hermann and Weigt, Carmen and Schipp, Dorothea and Werwitzke, Sonja and Tiede, Andreas},
  title = {Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia A},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2024},
  doi = {10.1016/j.jtha.2024.06.010}
}
Kostenlos starten →